期刊
LANCET ONCOLOGY
卷 17, 期 2, 页码 E62-E69出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(15)00388-5
关键词
-
类别
资金
- LYRIC [INCa_4664]
- Project EuroSARC [FP7-278742]
- NetSARC
- Reseau de Reference en Pathologie des Sarcomes
- Labex DevweCan [ANR-10-LABX-0061]
Rare cancers are defined by an incidence of less than six per 100 000 people per year. They represent roughly 20% of all human cancers and are associated with worse survival than are so-called frequent tumours, because of delays to accurate diagnosis, inadequate treatments, and fewer opportunities to participate in clinical trials (because of a paucity of dedicated trials from both academic and industrial sponsors). In this Series paper, we discuss how these challenges can be addressed by research consortia and suggest the integration of these consortia with reference networks, which gather multidisciplinary expert centres, for management of rare tumours.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据